225 related articles for article (PubMed ID: 28791261)
1. Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.
Paulis G; Paulis A; Romano G; Barletta D; Fabiani A
Res Rep Urol; 2017; 9():129-139. PubMed ID: 28791261
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.
Paulis G; Barletta D; Turchi P; Vitarelli A; Dachille G; Fabiani A; Gennaro R
Res Rep Urol; 2016; 8():1-10. PubMed ID: 26770906
[TBL] [Abstract][Full Text] [Related]
3. Patients with Peyronie's disease achieve complete plaque regression after multimodal treatment with antioxidants: a case series.
Paulis G; De Giorgio G
J Med Case Rep; 2022 Oct; 16(1):359. PubMed ID: 36207748
[TBL] [Abstract][Full Text] [Related]
4. Disappearance of Plaque Following Treatment with Antioxidants in Peyronie's Disease Patients-A Report of 3 Cases.
Paulis G; De Giorgio G
Clin Pract; 2022 Dec; 12(6):1020-1033. PubMed ID: 36547113
[TBL] [Abstract][Full Text] [Related]
5. Complete Plaque Regression in Patients with Peyronie's Disease After Multimodal Treatment with Antioxidants: A Report of 2 Cases.
Paulis G; De Giorgio G
Am J Case Rep; 2022 Apr; 23():e936146. PubMed ID: 35430575
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
[TBL] [Abstract][Full Text] [Related]
7. Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study.
Paulis G; Cavallini G; Brancato T; Alvaro R
Inflamm Allergy Drug Targets; 2013 Feb; 12(1):61-7. PubMed ID: 23004005
[TBL] [Abstract][Full Text] [Related]
8. Review of Management Options for Patients With Atypical Peyronie's Disease.
Yafi FA; Hatzichristodoulou G; DeLay KJ; Hellstrom WJ
Sex Med Rev; 2017 Apr; 5(2):211-221. PubMed ID: 27544298
[TBL] [Abstract][Full Text] [Related]
9. Full Regression of Peyronie's Disease Plaque Following Combined Antioxidant Treatment: A Three-Case Report.
Paulis G; De Giorgio G
Antioxidants (Basel); 2022 Aug; 11(9):. PubMed ID: 36139736
[TBL] [Abstract][Full Text] [Related]
10. Role of Oxidative Stress in Peyronie's Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants.
Paulis G; De Giorgio G; Paulis L
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555611
[TBL] [Abstract][Full Text] [Related]
11. Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie's disease (chronic inflammation of the tunica albuginea). Results of a controlled study.
Paulis G; Cavallini G; Giorgio GD; Quattrocchi S; Brancato T; Alvaro R
Inflamm Allergy Drug Targets; 2013 Dec; 12(6):403-9. PubMed ID: 24304332
[TBL] [Abstract][Full Text] [Related]
12. Surgical Outcomes of Plaque Excision and Grafting and Supplemental Tunica Albuginea Plication for Treatment of Peyronie's Disease With Severe Compound Curvature.
Chow AK; Sidelsky SA; Levine LA
J Sex Med; 2018 Jul; 15(7):1021-1029. PubMed ID: 29802005
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.
Cocci A; Cito G; Urzì D; Minervini A; Di Maida F; Sessa F; Mari A; Campi R; Falcone M; Capece M; Morelli G; Cacciamani G; Rizzo M; Polito C; Giammusso B; Morgia G; Verze P; Salonia A; Cai T; Mirone V; Mondaini N; Russo GI
J Sex Med; 2018 Oct; 15(10):1472-1477. PubMed ID: 30245025
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies.
Paulis G; Brancato T
Inflamm Allergy Drug Targets; 2012 Feb; 11(1):48-57. PubMed ID: 22309083
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease.
Ibrahim A; Gazzard L; Alharbi M; Rompré-Brodeur A; Aube M; Carrier S
Sex Med; 2019 Dec; 7(4):459-463. PubMed ID: 31445974
[TBL] [Abstract][Full Text] [Related]
16. Management of Peyronie's disease--a review.
Tunuguntla HS
World J Urol; 2001 Aug; 19(4):244-50. PubMed ID: 11550782
[TBL] [Abstract][Full Text] [Related]
17. Effect of Penile Traction and Vacuum Erectile Device for Peyronie's Disease in an Animal Model.
Lin H; Liu C; Wang R
J Sex Med; 2017 Oct; 14(10):1270-1276. PubMed ID: 28923308
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease.
Serefoglu EC; Smith TM; Kaufman GJ; Liu G; Yafi FA; Hellstrom WJG
Urology; 2017 Sep; 107():155-160. PubMed ID: 28554517
[TBL] [Abstract][Full Text] [Related]
19. Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease.
Novak TE; Bryan W; Templeton L; Sikka S; Hellstrom WJ
J La State Med Soc; 2001 Jul; 153(7):358-63. PubMed ID: 11519219
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pentoxifylline in Peyronie's disease: Clinical case of a young man.
Dell'Atti L; Ughi G
Arch Ital Urol Androl; 2014 Sep; 86(3):237-8. PubMed ID: 25308598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
